Shared parameter model for competing risks and different data summaries in meta‐analysis: Implications for common and rare outcomes

This paper considers the problem in aggregate data meta‐analysis of studies reporting multiple competing binary outcomes and of studies using different summary formats for those outcomes. For example, some may report numbers of patients with at least one of each outcome while others may report the total number of such outcomes. We develop a shared parameter model on hazard ratio scale accounting for different data summaries and competing risks. We adapt theoretical arguments from the literature to demonstrate that the models are equivalent if events are rare. We use constructed data examples and a simulation study to find an event rate threshold of approximately 0.2 above which competing risks and different data summaries may bias results if no adjustments are made. Below this threshold, simpler models may be sufficient. We recommend analysts to consider the absolute event rates and only use a simple model ignoring data types and competing risks if all of underlying events are rare (below our threshold of approximately 0.2). If one or more of the absolute event rates approaches or exceeds our informal threshold, it may be necessary to account for data types and competing risks through a shared parameter model in order to avoid biased estimates.

[1]  J. Mann,et al.  Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. , 2012, Archives of general psychiatry.

[2]  Peter Cummings,et al.  The relative merits of risk ratios and odds ratios. , 2009, Archives of pediatrics & adolescent medicine.

[3]  Nicky J Welton,et al.  Network meta-analysis with competing risk outcomes. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  David J. Lunn,et al.  The BUGS Book: A Practical Introduction to Bayesian Analysis , 2013 .

[5]  Wim Van den Noortgate,et al.  Assessing meta‐regression methods for examining moderator relationships with dependent effect sizes: A Monte Carlo simulation , 2017, Research synthesis methods.

[6]  Kerrie Mengersen,et al.  Multivariate meta‐analysis , 2003, Statistics in medicine.

[7]  Guido Schwarzer,et al.  Meta‐analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence functions , 2016, Research synthesis methods.

[8]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[9]  Nicky J Welton,et al.  Evidence Synthesis for Decision Making in Healthcare , 2012 .

[10]  J. T. Wulu,et al.  Regression analysis of count data , 2002 .

[11]  Nicky J Welton,et al.  A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials , 2014 .

[12]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[13]  Alex J. Sutton,et al.  Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches , 2006 .

[14]  Nicky J Welton,et al.  Controlling ecological bias in evidence synthesis of trials reporting on collapsed and overlapping covariate categories , 2010, Statistics in medicine.

[15]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[16]  Michael J Crowther,et al.  Using simulation studies to evaluate statistical methods , 2017, Statistics in medicine.

[17]  Nicola J Cooper,et al.  Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes , 2014, BMC Medical Research Methodology.

[18]  Giovanni Parmigiani,et al.  Meta-Analysis of Migraine Headache Treatments: Combining Information from Heterogeneous Designs , 1999 .

[19]  A. Lazo-Langner,et al.  New oral anticoagulants , 2013, Canadian Medical Association Journal.

[20]  Nicky J Welton,et al.  NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials , 2011 .

[21]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[22]  F Gueyffier,et al.  Multivariate meta-analysis using individual participant data , 2014 .

[23]  M. Coleman,et al.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.

[24]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[25]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[26]  F Mosteller,et al.  Meta-analysis of multiple outcomes by regression with random effects. , 1998, Statistics in medicine.

[27]  S. Dias,et al.  Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities , 2018, PharmacoEconomics.

[28]  David C Hoaglin,et al.  Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  A E Ades,et al.  A chain of evidence with mixed comparisons: models for multi‐parameter synthesis and consistency of evidence , 2003, Statistics in medicine.

[30]  Neil Hawkins,et al.  Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial , 2010, BMC medical research methodology.

[31]  Nicky J Welton,et al.  Evidence Synthesis for Decision Making in Healthcare: Welton/Evidence Synthesis for Decision Making in Healthcare , 2012 .

[32]  J. Sterne,et al.  Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. , 2017, Health technology assessment.

[33]  Gilbert MacKenzie,et al.  The Statistical Analysis of Failure Time Data , 1982 .

[34]  Deborah M Caldwell,et al.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis , 2017, BMJ.

[35]  A E Ades,et al.  Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies , 2010, Research Synthesis Methods.

[36]  A E Ades,et al.  Mixed treatment comparison with multiple outcomes reported inconsistently across trials: Evaluation of antivirals for treatment of influenza A and B , 2008, Statistics in medicine.

[37]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[38]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[39]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[40]  R. Hart,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 2000 .

[41]  Ingram Olkin,et al.  A method for the meta‐analysis of mutually exclusive binary outcomes , 2008, Statistics in medicine.